Plasma steroid concentrations reflect acute disease severity and normalise during recovery in people hospitalised with COVID-19.

Collapse authors list.
Devine, Kerri, Russell, Clark D, Blanco, Giovanny R, Walker, Brian R, Homer, Natalie ZM, Denham, Scott G, Simpson, Joanna P, Leavy, Olivia C, Elneima, Omer, McAuley, Hamish JC et al (show 25 more authors) , Shikotra, Aarti, Singapuri, Amisha, Sereno, Marco, Saunders, Ruth M, Harris, Victoria C, Houchen-Wolloff, Linzy, Greening, Neil J, Lone, Nazir I, Thorpe, Mathew, Greenhalf, William ORCID: 0000-0002-1865-3195, Chalmers, James D, Ho, Ling-Pei, Horsley, Alex, Marks, Michael, Raman, Betty, Moore, Shona C ORCID: 0000-0001-8610-2806, Dunning, Jake, Semple, Malcolm G ORCID: 0000-0001-9700-0418, Andrew, Ruth, Wain, Louise V, Evans, Rachael A, Brightling, Christopher E, Kenneth Baillie, John, Reynolds, Rebecca M and ISARIC4C Investigators and PHOSP-COVID Study Collaborative Group, (2024) Plasma steroid concentrations reflect acute disease severity and normalise during recovery in people hospitalised with COVID-19. Clinical endocrinology, 100 (4). pp. 317-327.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Objective</h4>Endocrine systems are disrupted in acute illness, and symptoms reported following coronavirus disease 2019 (COVID-19) are similar to those found with clinical hormone deficiencies. We hypothesised that people with severe acute COVID-19 and with post-COVID symptoms have glucocorticoid and sex hormone deficiencies.<h4>Design/patients</h4>Samples were obtained for analysis from two UK multicentre cohorts during hospitalisation with COVID-19 (International Severe Acute Respiratory Infection Consortium/World Health Organisation [WHO] Clinical Characterization Protocol for Severe Emerging Infections in the UK study), and at follow-up 5 months after hospitalisation (Post-hospitalisation COVID-19 study).<h4>Measurements</h4>Plasma steroids were quantified by liquid chromatography-mass spectrometry. Steroid concentrations were compared against disease severity (WHO ordinal scale) and validated symptom scores. Data are presented as geometric mean (SD).<h4>Results</h4>In the acute cohort (n = 239, 66.5% male), plasma cortisol concentration increased with disease severity (cortisol 753.3 [1.6] vs. 429.2 [1.7] nmol/L in fatal vs. least severe, p < .001). In males, testosterone concentrations decreased with severity (testosterone 1.2 [2.2] vs. 6.9 [1.9] nmol/L in fatal vs. least severe, p < .001). In the follow-up cohort (n = 198, 62.1% male, 68.9% ongoing symptoms, 165 [121-192] days postdischarge), plasma cortisol concentrations (275.6 [1.5] nmol/L) did not differ with in-hospital severity, perception of recovery, or patient-reported symptoms. Male testosterone concentrations (12.6 [1.5] nmol/L) were not related to in-hospital severity, perception of recovery or symptom scores.<h4>Conclusions</h4>Circulating glucocorticoids in patients hospitalised with COVID-19 reflect acute illness, with a marked rise in cortisol and fall in male testosterone. These findings are not observed 5 months from discharge. The lack of association between hormone concentrations and common post-COVID symptoms suggests steroid insufficiency does not play a causal role in this condition.

Item Type:	Article
Uncontrolled Keywords:	ISARIC4C Investigators and PHOSP-COVID Study Collaborative Group
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	13 Mar 2024 09:22
Last Modified:	13 Mar 2024 09:22
DOI:	10.1111/cen.15012
Open Access URL:	https://doi.org/10.1111/cen.15012
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3179362